Comparative cardiovascular outcomes of renin–angiotensin system inhibitors in patients receiving maintenance hemodialysis: a large real-world cohort study
Jheng-Yan Wu, Keng-Wei Lee, Sheng-Chi Huang, Hsuan-Yuan Chang, Yu-Min Lin · 2026
Read Comparative cardiovascular outcomes of renin–angiotensin system inhibitors in patients receiving maintenance hemodialysis: a large real-world cohort study by Jheng-Yan Wu, Keng-Wei Lee, Sheng-Chi Huang, Hsuan-Yuan Chang, Yu-Min Lin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13312885.txt.
Description
Jheng-Yan Wu and colleagues compare, in a 2026 real-world cohort study, two families of blood pressure drugs in people on maintenance dialysis. Guidelines treat ACE inhibitors and angiotensin receptor blockers as interchangeable for these patients, but head-to-head cardiovascular evidence in the dialysis population was thin, so the team mined the TriNetX multi-institution network.
Adults with end-stage kidney disease who newly started either drug between 2006 and 2025 were matched one to one, leaving 55,894 patients. Over the first year, those starting a receptor blocker suffered fewer major cardiovascular events than those starting an ACE inhibitor, 30.3 percent against 35.0 percent in the reported figures, with lower stroke and death rates and similar heart attack and potassium outcomes. Checks designed to expose hidden bias came back clean. The authors caution that observation alone cannot prove cause.
Catalog record
| CREATOR | Jheng-Yan Wu, Keng-Wei Lee, Sheng-Chi Huang, Hsuan-Yuan Chang, Yu-Min Lin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33034 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |